ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1523570
This article is part of the Research TopicRenewed Insight into Cancer Mechanism and TherapyView all 34 articles
Ansofaxine Hydrochloride inhibits hepatocellular carcinoma growth and enhances targeted therapy through the EGFR/MAPK pathway
Provisionally accepted
Yongfei He1
Qiang Tao1Shutian Mo2Meifeng Chen2Jicai Wang1
Hang Zhai1
Shengjie Hong1Qiang Gao3
Guangquan Zhang1
Chuangye Han2*Xianjie Shi1*- 1The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
- 2First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi Zhuang Region, China
- 3The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hepatocellular carcinoma (HCC) is a common tumor that endangers health. Depression will affect the therapeutic effect of HCC, and depression and HCC promote and influence each other.Ansofaxine Hydrochloride is a novel antidepressant, and its anti-HCC effect remains to be confirmed.This study aimed to investigate the effect of Ansofaxine Hydrochloride on HCC and its molecular mechanism.In vivo experiments showed that Ansofaxine Hydrochloride has a synergistic effect of enhancingLenvatinib anti-HCC, enhancing peripheral blood DA level, promoting M1 macrophage infiltration, and enhancing immune anti-tumor effects, and is associated with the reduction of EGFR/MAPK pathway-related genes.Our study suggests that Ansofaxine Hydrochloride has anti-HCC and immunomodulatory effects, with the EGFR/MAPK pathway as a potential key mechanism of action.
Keywords: Hepatocellular Carcinoma, Ansofaxine hydrochloride, Network Pharmacology, EGFR/MAPK pathway, Depression
Received: 06 Nov 2024; Accepted: 07 Jul 2025.
Copyright: © 2025 He, Tao, Mo, Chen, Wang, Zhai, Hong, Gao, Zhang, Han and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chuangye Han, First Affiliated Hospital, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Region, China
Xianjie Shi, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.